Insmed price target lowered to $157 from $158 at Morgan Stanley

Morgan Stanley analyst Maxwell Skor lowered the firm’s price target on Insmed (INSM) to $157 from $158 and keeps an Equal Weight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.